2. Signaling Pathways
  3. GPCR/G Protein
  4. GCGR

GCGR

Glucagon Receptor

GCGR

Related Products

PDF 0.98 MB

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-172836S
    GLP-1 receptor agonist 17-d3
    		Agonist
    GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases.
    GLP-1 receptor agonist 17-d<sub>3</sub>
  • HY-13443F
    Exendin 4, biotin labeled
    Exendin 4, biotin labeled is a biological active peptide. (Biotin labeled HY-13443)
    Exendin 4, biotin labeled
  • HY-P3101A
    GLP-1(28-36)amide TFA
    GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects.
    GLP-1(28-36)amide TFA
  • HY-169707
    GCGR antagonist 3
    		Antagonist
    GCGR antagonist 3 (example 1) is an antagonist of the glucagon receptor (GCGR) and can be used in diabetes research.
    GCGR antagonist 3
  • HY-P10337
    OXM-7
    		Agonist
    OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism.
    OXM-7
  • HY-P3388
    Utreglutide
    		Agonist 98.42%
    Utreglutide is a potent glucagon-like peptide 1 (GLP-1) receptor agonit.
    Utreglutide
  • HY-P3608
    [Des-His1,Glu9] Glucagon
    		Antagonist
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes.
    [Des-His1,Glu9] Glucagon
  • HY-P5578A
    A8SGLP-1 TFA
    		Agonist
    A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function.
    A8SGLP-1 TFA
  • HY-P0211
    [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)
    		Antagonist
    [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human), a growth hormone releasing factor (GRF) analogue, is a vasoactive intestinal peptide (VIP) antagonist.
    [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)
  • HY-P0119S
    Lixisenatide (Leu-13C6,15N) TFA
    Lixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119). Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe?/? Irs2+/? mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation.
    Lixisenatide (Leu-<sup>13</sup>C<sub>6</sub>,<sup>15</sup>N) TFA
  • HY-118914
    Glucagon receptor antagonist inactive control
    		Control
    Glucagon receptor antagonist inactive control (Compound 2) is a compound structurally similar to the glucagon receptor (GCGR) antagonist Glucagon receptor antagonist (Compound 1) but lacks antagonistic activity against glucagon receptor (GCGR). Glucagon receptor antagonist inactive control can be used as a negative control to study mechanisms related to glucagon receptor-mediated signaling pathways.
    Glucagon receptor antagonist inactive control
  • HY-12735
    SCH 900822
    		Antagonist
    SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes.
    SCH 900822
  • HY-142162A
    (S,R)-LSN3318839
    		Control
    (S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar.
    (S,R)-LSN3318839
  • HY-12525A
    LGD-6972 sodium
    		Antagonist
    LGD-6972 sodium is a selective and orally active glucagon receptor antagonist. LGD-6972 sodium has the potential for type 2 diabetes research.
    LGD-6972 sodium
  • HY-125824A
    Danuglipron tromethamine
    		Agonist
    Danuglipron (PF-06882961) tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron tromethamine has the potential for type 2 diabetes research.
    Danuglipron tromethamine
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity